Significance of the genomic predictors of parity derived in the discovery phase and evaluated in the validation phase using logistic regression models: estimated coefficients, standard errors, and P values of parity scores and other clinical covariates in the validation phase
Classification tree | Tree AdaBoost | Support vector machine | Random forest | Neareast shrunken centroids | |
---|---|---|---|---|---|
β (SE) P | β (SE) P | β (SE) P | β (SE) P | β (SE) P | |
Parity scorea | 1.799 (0.98) 0.0657 | 4.726 (1.77) 0.0075 | 3.611 (1.77) 0.0414 | 4.122 (1.72) 0.0164 | 4.289 (1.30) 0.0010 |
BMI | –0.094 (0.13) 0.4640 | –0.169 (0.14) 0.2391 | –0.155 (0.14) 0.2705 | –0.176 (0.14) 0.2242 | –0.209 (0.14) 0.1358 |
Breast density | 0.931 (0.72) 0.1931 | 1.363 (0.81) 0.0923 | 1.182 (0.76) 0.1201 | 1.307 (0.79) 0.0959 | 1.071 (0.80) 0.1816 |
HRT duration | 0.037 (0.07) 0.5914 | 0.037 (0.07) 0.6063 | 0.022 (0.07) 0.7496 | 0.022 (0.07) 0.7591 | 0.048 (0.08) 0.5246 |
OC use | 1.003 (0.67) 0.1342 | 0.791 (0.70) 0.2602 | 0.797 (0.67) 0.2308 | 0.753 (0.68) 0.2662 | 0.769 (0.78) 0.3247 |
Smoking duration | –0.013 (0.02) 0.5331 | –0.019 (0.02) 0.3707 | –0.013 (0.02) 0.5307 | –0.015 (0.02) 0.4637 | –0.009 (0.02) 0.7087 |
aParity score is a woman's probability of being parous estimated using the genomic predictors of parity derived in the discovery phase. The significance of the parity scores was evaluated in the validation phase using logistic regression models with FTP as the response variable and parity score, BMI, breast density, HRT duration, OC use, and smoking history as predictors. Statistically significant P values are shown in bold.